Incident frailty
IL‐6 reduction
Of the 8620 participants who were not frail at baseline, 1080 (12.5%) became frail during the 5‐year follow‐up period. There was no difference in rate of incident frailty according to randomization over time, comparing those allocated to any dose of canakinumab as compared to placebo or in comparisons of each dose separately to placebo (Figure Effect of canakinumab on incident frailty (Cumulative incidence curves stratified by on‐treatment CRP and IL‐6 demonstrate a reduction in incident frailty among participants whose inflammatory markers were lower, irrespective of drug assignment category. For those assigned to placebo with CRP reduction, HR was 0.81 (95% CI 0.62–1.05) and for those assigned to active drug HR was 0.83 (95% CI 0.71–0.97) (Figure Effect of canakinumab on incident frailty according to on‐treatment CRP and IL‐6 reduction.